Rockwell Medical, Inc. to Present at 2019 Cantor Global Healthcare Conference
September 24 2019 - 4:30PM
Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the
"Company") today announced that Stuart Paul, Chief Executive
Officer, is scheduled to present at the 2019 Cantor Global
Healthcare Conference as follows:
Date: |
Wednesday, October 2, 2019 |
Time: |
10:05 a.m. Eastern Daylight Time |
Location: |
Intercontinental New York Barclay Hotel, NYC |
Webcast: |
http://wsw.com/webcast/cantor10/rmti/ |
The presentation will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the Company’s
website at www.rockwellmed.com, under the “Investors” section.
About Rockwell Medical Rockwell Medical is a
biopharmaceutical company dedicated to improving outcomes for
patients with anemia, with an initial focus on end-stage renal
disease (ESRD) and chronic kidney disease (CKD). Rockwell Medical's
exclusive renal drug therapy, Triferic, is the only FDA-approved
therapeutic indicated for iron replacement and maintenance of
hemoglobin in hemodialysis patients. The Company has developed
multiple formulations of Triferic (1) FDA-approved Dialysate
Triferic; and (2) I.V. Triferic, for which the Company filed a New
Drug Application in May 2019. The Company’s strategy is to bring
its therapeutics to market in the United States and to utilize
partners to develop and commercialize such therapeutics in
international markets. Rockwell Medical is also an established
manufacturer, supplier and leader in delivering high-quality
hemodialysis concentrates/dialysates to dialysis providers and
distributors in the U.S. and abroad. Please visit
www.rockwellmed.com for more information.
About Triferic Triferic is the only
FDA-approved therapy in the U.S. indicated to replace iron and
maintain hemoglobin in hemodialysis patients via dialysate during
each dialysis treatment. Triferic delivers approximately 5-7 mg
iron with every hemodialysis treatment to the bone marrow and
maintains hemoglobin without increasing iron stores (ferritin).
Unlike traditional IV iron products, Triferic donates iron
immediately and completely to transferrin (carrier of iron in the
body) upon entry into the blood and is then transported directly to
the bone marrow to be incorporated into hemoglobin, with no
increase in ferritin (stored iron and inflammation) and no reports
of anaphylaxis in over 1,000,000 patient administrations,
addressing a significant medical need in overcoming Functional Iron
Deficiency (FID) in ESRD patients. The Company has developed
multiple formulations of Triferic: (1) FDA-approved Dialysate
Triferic; and (2) I.V. Triferic, for which the Company filed a New
Drug Application in May 2019 with a PDUFA date of March 28, 2020.
Please visit www.triferic.com to view the Triferic mode-of-action
(MOA) video and for more information.
Important Safety InformationSerious
hypersensitivity reactions, including anaphylactic-type reactions,
some of which have been life-threatening and fatal, have been
reported in patients receiving parenteral iron products. Patients
may present with shock, clinically significant hypotension, loss of
consciousness, and/or collapse. Monitor patients for signs and
symptoms of hypersensitivity during and after hemodialysis until
clinically stable. Personnel and therapies should be immediately
available for the treatment of serious hypersensitivity reactions.
Hypersensitivity reactions have been reported in 1 (0.3%) of 292
patients receiving Triferic in two randomized clinical trials.
Iron status should be determined on pre-dialysis blood samples.
Post dialysis serum iron parameters may overestimate serum iron and
transferrin saturation.
The most common adverse reactions (≥3% and at least 1% greater
than placebo) in controlled clinical studies include: procedural
hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in
extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back
pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%),
asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula
thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).
For more information, including full prescribing information,
visit: http://www.triferic.com.
Investor Relations:Lisa M. WilsonIn-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Sep 2023 to Sep 2024